Setmelanotide
Intervention1 paper3 findingsPubChem 11993702
Outcomes
3HOMA-IR
downin humans1Very low certainty
1 study
HOMA-IR
downin humans1Very low certainty
Setmelanotide decreases HOMA-IR in humans.
Human trialBardet-Biedl syndrome12 monthsmalesn = 1
Sequential liraglutide and setmelanotide therapy in Bardet-Biedl Syndrome: metabolic and renal outcomes in a real-world case report and literature review · Nephron · 15 Sep 2026
Liver stiffness
downin humans1Very low certainty
1 study
Liver stiffness
downin humans1Very low certainty
Setmelanotide decreases liver stiffness in humans.
Human trialBardet-Biedl syndrome12 monthsmalesn = 1
Sequential liraglutide and setmelanotide therapy in Bardet-Biedl Syndrome: metabolic and renal outcomes in a real-world case report and literature review · Nephron · 15 Sep 2026
Body weight
downin humans1−11%Very low certainty
1 study
Body weight
downin humans1−11%Very low certainty
Setmelanotide decreases body weight in humans (-10.5%).
Human trialBardet-Biedl syndrome12 monthsmalesn = 1
Sequential liraglutide and setmelanotide therapy in Bardet-Biedl Syndrome: metabolic and renal outcomes in a real-world case report and literature review · Nephron · 15 Sep 2026